Abstract
To evaluate study designs and the influence of dispersion of body size, body composition and maturation of clearance or reliable estimation of allometric exponents. Non-linear mixed effects modeling and parametric bootstrap were employed to assess how the study sample size, number of observations per subject, between subject variability (BSV) and dispersion of size distribution affected estimation bias and uncertainty of allometric exponents. The role of covariate model misspecification was investigated using a large data set ranging from neonates to adults. A decrease in study sample size, number of observations per subject, an increase in BSV and a decrease in dispersion of size distribution, increased the uncertainty of allometric exponent estimates. Studies conducted only in adults with drugs exhibiting normal (30%) BSV in clearance may need to include at least 1000 subjects to be able to distinguish between allometric exponents of 2/3 and 1. Nevertheless, studies including both children and adults can distinguish these exponents with only 100 subjects. A marked bias of 45% (95%CI 41–49%) in the estimate of the allometric exponent of clearance was obtained when maturation and body composition were ignored in infants. A wide dispersion of body size (e.g. infants, children and adults) is required to reliably estimate allometric exponents. Ignoring differences in body composition and maturation of clearance may bias the exponent for clearance. Therefore, pharmacometricians should avoid estimating allometric exponent parameters without suitable designs and covariate models. Instead, they are encouraged to rely on the well-developed theory and evidence that clearance and volume parameters in humans scale with theory-based exponents.
Similar content being viewed by others
Data availability
Covariate data were obtained from a previously published study of busulfan with permission of the first author [34].
Code availability
Available as supplementary material.
References
West GB, Brown JH (2005) The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 208:1575–1592
Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25–36
Ings RM (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:1201–1231
Hu TM, Hayton WL (2001) Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3:E29
Mahmood I (2010) Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci 99:2927–2933
Holford NHG, Anderson BJ (2017) Allometric size: the scientific theory and extension to normal fat mass. Eur J Pharm Sci 109(Supplement):S59–S64
Holford N (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329–332
Holford N (2013) A pharmacokinetics standard for babies and adults. J Pharm Sci 102:2941–2952
Anderson BJ, Holford NHG (2011) Tips and traps analyzing pediatric PK data. Pediatr Anesth 21:222–237
Goulooze SC, Völler S, Välitalo PAJ, Calvier EAM, Aarons L, Krekels EHJ, Knibbe CAJ (2019) The influence of normalization weight in population pharmacokinetic covariate models. Clin Pharmacokinet 58:131–138
West GB, Brown JH, Enquist BJ (1999) The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677–1679
West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122–126
Peters HP (1983) Physiological correlates of size. In: Beck R, Birks HJB, Conner EF (eds) Chapter 4. The ecological implications of body size. Cambridge University Press, Cambridge, pp 48–53
Brody S, Proctor RC, Ashworth US (1934) Basal metabolism, endogenous nitrogen, creatinine, and sulphur excretions as functions of body weight. Univ Mo Agric Exp Stn Res Bull 220:1–40
Kleiber M (1932) Body size and metabolism. Hilgardia 6:315–333
Stahl WR (1967) Scaling of respiratory variables in mammals. J Appl Physiol 22:453–600
Cortinez LI, Anderson BJ, Penna A, Olivares L, Muñoz HR, Holford NHG, Struys MMRF, Sepulveda P (2010) Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. BJA 105:448–456
Anderson BJ, Holford NH (2017) What is the best size predictor for dose in the obese child? Paediatr Anaesth 27(12):1176–1184
Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–332
Huang Q, Riviera JE (2014) The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert Opin Drug Metab Toxicol 10:1241–1253
Knibbe CAJ, Zuideveld KP, Arts LP, Kuks PF, Danhof M (2005) Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 59:705–711
Dodds PS, Rothman DH, Weitz JS (2001) Re-examination of the “3/4-law” of metabolism. J Theor Biol 209:9–27
Agutter PS, Wheatley DN (2004) Metabolic scaling: consensus or controversy? Theor Biol Med Model 1:13
Bokma F (2004) Evidence against universal metabolic allometry. Funct Ecol 18:184–187
Glazier DS (2005) Beyond the “3/4-power law”: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev 80:611–662
White CR, Cassey P, Blackburn TM (2007) Allometric exponents do not support a universal metabolic allometry. Ecology 88:315–323
Kolokotrones T, Van S, Deeds EJ, Fontana W (2010) Curvature in metabolic scaling. Nature 464:753–756
Benedict FG (1938) Vital energetics: a study in comparative basal metabolism. Carnegie Institution, Washington
White CR, Seymour RS (2003) Mammalian basal metabolic rate is proportional to body mass 2/3. Proc Natl Acad Sci USA 100:4046–4049
Germovsek E, Barker CIS, Sharland M, Standing JF (2017) Scaling clearance in paedriatic pharmacokinetics: all models are wrong, which are useful? Br J Clin Pharmacol 83:777–790
Calvier EA, Krekels EH, Valitalo PA, Rostami-Hodjegan A, Tibboel D, Danhof M, Knibbe CA (2017) Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet 56:273–85
European Medicine Agency. Modelling and simulation: questions and answers. “Should fixed or estimated values be used in paediatric pharmacokinetic models?” November 2018. Available at: https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/modelling-simulation-questions-answers. Accessed 30 Mar 2021
Sinha J, Al-Sallami HS, Duffull SB (2019) Choosing the allometric exponent in covariate model building. Clin Pharmacokinet 58:89–100
McCune JS, Bemer MJ, Barrett JS, Baker KS, Gamis AS, Holford NHG (2014) Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res 20:754–63
Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051–1065
Al-Sallami HS, Cheah SL, Han SY, Liew J, Lim J, Ng MA et al (2014) Between-subject variability: should high be the new normal? Eur J Clin Pharmacol 70:1403–1404
De Castro FA, Piana C, Simoes B, Lanchote VL, Della Pasqua O (2015) Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. Br J Clin Pharmacol 80:618–29
Chow SC, Zheng J (2019) The use of 95% CI or 90% CI for drug product development—a controversial issue? J Biopharm Stat 29:834–844
The R Project for Statistical Computing. Available at: https://www.r-project.org/. Accessed 30 Mar 2021
Mahmood I (2012) Prediction of clearance and volume of distribution in the obese from normal weight subjects. Clin Pharmacokinet 51:527–542
Gonzalez D, Laughon MM, Smith PB, Ge S, Ambalavanan N, Atz A et al (2019) Population pharmacokinetics of sildenafil in extremely premature infants. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.14111
Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, Stone JA (2017) Evaluation of dosing strategy for pembrolizumab for oncology indications. J ImmunoTher Cancer 5:43
Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227
Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028–1040
White CR, Seymour RS (2005) Allometric scaling of mammalian metabolism. J Exp Biol 208:1611–1619
Rowland M, Tozer TN (2011) Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Lippincott Williams & Wilkins, Philadelphia
West GB (2012) The importance of quantitative systemic thinking in medicine. Lancet 379:1551–1559
Mahmood I (2014) Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet 53:327–346
Bonate PL (1999) The effect of collinearity on parameter estimates in nonlinear mixed effects models. Pharm Res 16:709–717
Holford NH, Ma SC, Anderson BJ (2012) Prediction of morphine dose in humans. Paediatr Anaesth 22:209–222
Sumpter A, Holford NHG (2012) A model for fat free mass in humans from very premature neonates to young adults. PAGANZ https://www.paganz.org/abstracts/a-model-for-fat-free-mass-in-humans-from-very-premature-neonates-to-young-adults/. Accessed 31 Jan 2019
Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB (2015) Prediction of fat-free mass in children. Clin Pharmacokinet 54:1169–1178
Acknowledgements
We gratefully acknowledge Dr Jeannine McCune for allowing us to use the covariate data from her study of the pharmacokinetics of busulfan [34].
Funding
This work received no specific funding.
Author information
Authors and Affiliations
Contributions
MGS and NH designed the study, MGS performed the calculations, MGS, NH, GB and JD wrote and take responsibility for the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Mario González-Sales, Nick Holford, Guillaume Bonnefois and Julie Desrochers declare no conflicts of interest.
Ethical approval
No ethical approval was required for this simulation-based work.
Informed consent
All authors consent for publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
González-Sales, M., Holford, N., Bonnefois, G. et al. Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates. J Pharmacokinet Pharmacodyn 49, 151–165 (2022). https://doi.org/10.1007/s10928-021-09788-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-021-09788-3